Known targets — ChEMBL curated mechanism
HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9
The experimentally established mechanism targets of Entinostat. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 known ✓ | Q13547 | 19/20 | 0.93 |
| ▸ | HDAC3 known ✓ | O15379 | 11/20 | 0.93 |
| ▸ | HDAC2 known ✓ | Q92769 | 11/20 | 0.93 |
| ▸ | HDAC8 known ✓ | Q9BY41 | 9/20 | 0.93 |
| ▸ | HDAC4 known ✓ | P56524 | 8/20 | 0.93 |
| ▸ | HDAC7 known ✓ | Q8WUI4 | 8/20 | 0.93 |
| ▸ | HDAC10 known ✓ | Q969S8 | 8/20 | 0.93 |
| ▸ | HDAC11 known ✓ | Q96DB2 | 8/20 | 0.93 |
| ▸ | HDAC6 known ✓ | Q9UBN7 | 8/20 | 0.93 |
| ▸ | HDAC9 known ✓ | Q9UKV0 | 8/20 | 0.93 |
| ▸ | HDAC5 known ✓ | Q9UQL6 | 8/20 | 0.93 |
| ▸ | KDM1A | O60341 | 1/20 | 0.93 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.93 |
| ▸ | F3 | P13726 | 1/20 | 0.93 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.93 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
| ▸ | NAMPT | P43490 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Entinostat SCHEMBL2408179 | 0.97 | HDAC1 (0.91) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL29499905 | 0.96 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL148309 | 0.96 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL29387345 | 0.96 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL29838042 | 0.96 | HDAC1 (1.00) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2409897 | 0.95 | HDAC1 (0.98) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2407986 | 0.95 | HDAC1 (0.98) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2412431 | 0.93 | HDAC1 (0.94) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| Entinostat SCHEMBL2413749 | 0.93 | HDAC1 (0.93) | HDAC1HDAC3HDAC2HDAC8HDAC4 | |
| SCHEMBL2415852 | 0.92 | HDAC1 (0.92) | HDAC1HDAC3HDAC2HDAC8HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9018176-B2 | Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-04-28 | — | — | US | disclosed |
| US-8026239-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-27 | — | — | US | disclosed |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-07 | — | — | US | disclosed |
| CN-101686970-A | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | BAYER SCHERING PHARMA AG | 2010-03-31 | — | — | CN | disclosed |
| US-7687525-B2 | Cell differentiation inducer | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-30 | — | — | US | disclosed |
| US-RE40703-E1 | Cell differentiation inducer, benzamide compounds | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-04-28 | — | — | US | disclosed |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | BAYER SCHERING PHARMA AG (DE) | 2009-02-19 | — | — | US | disclosed |
| EP-2008658-A1 | Synergistic combination of anthranilamide pyridinureas and benzamide derivatives | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-12-31 | — | — | EP | disclosed |
| US-20080188489-A1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-08-07 | — | — | US | disclosed |
| US-7317028-B2 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2008-01-08 | — | — | US | disclosed |
| US-20050054647-A1 | New pharmaceutical combination | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2005-03-10 | — | — | US | disclosed |
| WO-2005007158-A1 | TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA | THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION (US) | 2005-01-27 | — | — | WO | disclosed |
| US-6841565-B1 | Benzamide derivatives which induce apoptosis in inactive, non-proliferating B-CLL cells | THE OHIO STATE UNIVERSITY (US) | 2005-01-11 | — | — | US | disclosed |
| US-6794392-B1 | Cell differentiation inducer | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-09-21 | — | — | US | disclosed |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | SCHERING AKTIENGESELLSCHAFT | 2004-07-29 | — | — | US | disclosed |
| WO-2004058234-A2 | PHARMACEUTICAL COMBINATIONS OF PHTHALAZINE VEGF INHIBITORS AND BENZAMIDE HDAC INHIBITORS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-07-15 | — | — | WO | disclosed |
| EP-1437346-A1 | Benzamide derivatives useful as cell differentiation inducers | Schering AG (DE) | 2004-07-14 | — | — | EP | disclosed |
| EP-0847992-B1 | Benzamide derivatives, useful as cell differentiation inducers | SCHERING AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| US-6174905-B1 | AS CARCINOSTATIC AGENT TO A HEMATOLOGIC MALIGNANCY AND A SOLID CARCINOMA | MITSUI CHEMICALS, INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0847992-A1 | Benzamide derivatives, useful as cell differentiation inducers | Mitsui Chemicals, Inc. (JP) | 1998-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080188489-A1 | Cell differentiation inducer | MCL1, MYADM, MYD88 | HDAC1 150/4885HDAC3 618/4885HDAC2 170/4885 |
| US-20040147569-A1 | Antitumor agents; autoimmune disease; skin disorders; anticancer agents | MCL1, MYADM, PDCD1 | HDAC1 81/4885HDAC3 807/4885HDAC2 204/4885 |
| US-20100256201-A1 | CELL DIFFERENTIATION INDUCER | MCL1, MYADM, MYD88 | HDAC1 163/4885HDAC3 680/4885HDAC2 183/4885 |
| US-20050054647-A1 | New pharmaceutical combination | VEGFA, INHA, PGF | HDAC1 976/4885HDAC3 1616/4885HDAC2 1101/4885 |
| US-20090048292-A1 | SYNERGISTIC COMBINATION | HDAC1, HDAC2, HDAC11 | HDAC1 1/4885HDAC3 4/4885HDAC2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.